Evocutis, the skincare products testing group, managed to double revenues in the year to July 31st.
Turnover from commercial deals jumped from £0.22m to £0.46m, helped by collaboration and consultancy agreements with consumer healthcare companies.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The adjusted operating loss narrowed to £0.91m, from £1.09m previously. The loss per share reduced from 0.90p to 0.88p.
"These results show that the integration of Syntopix and Leeds Skin into Evocutis has led to significant growth in collaborations with major multi-national companies. Our collaborators are seeking the skill base at the core of Evocutis that enables them to strengthen their brands by providing scientific data that supports product claims," said interim Chief Executive Officer Gwyn Humphreys.
"Evocutis aims to grow these relationships over the coming twelve months, and to increase the availability of LabSkin for those companies who wish to carry out research in-house rather than by contract relationships with Evocutis."
-
Romance scam nets £428k – the red flags most missLove and friendship is big business for fraudsters who tricked unsuspecting Brits out of more than £100 million last year. What can be done about it?
-
‘We’ve saved hundreds of pounds in energy by installing solar panels’A couple say they have cut their energy bills by hundreds of pounds thanks to solar panels, and they hope to recoup the cost of the installation within a decade
